Annemarie Moseley

Dr. Annemarie Moseley currently serves as ImmunoGenesis’ acting Chief Medical Officer, where she is responsible for leading the company’s clinical programs. Dr. Moseley delivers more than 20 years of executive experience in the biotech industry. She most recently served as CEO of Sandhill Therapeutics and Executive Vice President of Operations at Bellicum Pharmaceuticals. Dr. Moseley earned a Ph.D. in Physiology and Biochemistry from Utah State University as well as an MD from Baylor College of Medicine, where she also completed a residency in Internal Medicine, a clinical investigator program in Immunology, and a clinical stem cell gene therapy fellowship in Medical and Molecular Genetics.